Bavarian Nordic A/S (BVNRY)
11.16
-0.06
(-0.58%)
USD |
OTCM |
Sep 24, 16:00
Bavarian Nordic Research and Development Expense (Annual) : 117.03M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 117.03M |
| December 31, 2024 | 122.12M |
| December 31, 2023 | 320.44M |
| December 31, 2022 | 166.23M |
| December 31, 2021 | 62.69M |
| December 31, 2020 | 51.76M |
| December 31, 2019 | 60.98M |
| December 31, 2018 | 60.74M |
| December 31, 2017 | 67.66M |
| December 31, 2016 | 68.52M |
| December 31, 2015 | 56.62M |
| December 31, 2014 | 84.70M |
| Date | Value |
|---|---|
| December 31, 2013 | 87.29M |
| December 31, 2012 | 59.11M |
| December 31, 2011 | 47.68M |
| December 31, 2010 | 36.82M |
| December 31, 2009 | 29.35M |
| December 31, 2008 | 24.40M |
| December 31, 2007 | 39.68M |
| December 31, 2006 | 18.26M |
| December 31, 2005 | 18.13M |
| December 31, 2004 | 17.87M |
| December 31, 2003 | 12.21M |
| December 31, 2002 | 7.117M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Evaxion AS | 9.691M |
| Genmab A/S | 1.564B |
| Ascendis Pharma A/S | 333.10M |
| Zealand Pharma A/S | 239.48M |
| Agenus, Inc. | 79.34M |